Sunitinib paves the way for targeted therapies in neuroendocrine tumors. (Q39775309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Sunitinib paves the way for targeted therapies in neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Pascal Hammel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Eric Raymond

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Philippe Ruszniewski

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

13 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

253-254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19911111%20AND%20SRC:MED&resulttype=core&format=json

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

12 February 2020

cites work

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Molecular basis for sunitinib efficacy and future clinical development

1 reference

12 December 2020

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

1 reference

12 December 2020

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

12 December 2020

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer

1 reference

12 December 2020